Fezolinetant
Fezolinetant reduces hot flash frequency by approximately 60%, exceeding the effectiveness of antidepressants. Fezolinetant acts on the hypothalamus to block the NK3 receptor signaling pathway that triggers vasomotor symptoms. Fezolinetant…
1 sources - 4 claims
Fezolinetant reduces hot flash frequency by approximately 60%, exceeding the effectiveness of antidepressants. Fezolinetant acts on the hypothalamus to block the NK3 receptor signaling pathway that triggers vasomotor symptoms. Fezolinetant requires liver enzyme monitoring at 3, 6, and 9 months after initiation due to risk of hepatic injury. Fezolinetant is an appropriate option for women who cannot or choose not to use hormone therapy.